Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo has received approval in Japan to manufacture and market Rezaltas combination tablets, LD and HD, for the treatment of hypertension.
Subscribe to our email newsletter
Rezaltas is a combination drug featuring the Daiichi Sankyo-developed olmesartan medoxomil (Olmetec), a high-affinity ARB (angiotensin receptor blocker). It also contains azelnidipine (Calblock), a long-acting CCB (calcium channel blocker), that the company researched and developed with Ube Industries.
The LD tablet incorporates 10mg of olmesartan medoxomil and 8mg of azelnidipine. The HD tablet employs 20mg and 16 mg, respectively, of these substances.
Daiichi Sankyo has combined olmesartan medoxomil, which has proven powerful in lowering blood pressure among ARBs, with azelnidipine, a CCB that delivers ongoing decreases in blood pressure while minimising sympathomimetic hyperactivity.
The company said that the clinical studies demonstrated that Rezaltas consistently suppresses blood pressure for 24 hours while offering tolerance.